A Phase 3 interventional study of insulin degludec and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-22.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 53rd largest by enrollment, is one of 12 that started in 2010, is one of 49 in phase 3, and was the 16th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 12 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 27 open now, 31 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 249th largest by enrollment of the 430 interventional ones that give a count, is one of 25 that started in 2010, is one of 187 in phase 3, and was the 199th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 645 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess the implications of switching from insulin glargine (IGlar) to insulin degludec (IDeg) in subjects with type 2 diabetes mellitus.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's enrollment of 143 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin glargine
Drug: insulin degludec
Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
HbA1c (Glycosylated Haemoglobin)
HbA1C at week 4 and 16
Time frame: Week 4 and Week 16
Fasting Plasma Glucose (FPG)
FPG at week 4 and 16
Time frame: Week 4 and Week 16
Change in Body Weight
Change from baseline in body weight after week 4 and after week 16
Time frame: Week 0, Week 4, Week 16
Rate of Treatment Emergent Adverse Events (AEs)
Corresponds to rate of AEs per 100 patient years of exposure. Mild AEs: no or transient symptoms, no interference with subject's daily activities. Moderate AEs: marked symptoms, moderate interference with subject's daily activities. Severe AEs: considerable interference with subject's daily activities, unacceptable. Serious adverse event (SAE): AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect
Time frame: Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
Rate of Confirmed Hypoglycaemic Episodes
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.
Time frame: Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
Rate of Nocturnal Confirmed Hypoglycaemic Episodes
Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occuring between 00:01 and 05:59 a.m.
Time frame: Weeks 0-4 (IGlar), Weeks 4-16 (IDeg 3TW)
The trial was conducted at 27 sites in the United States of America (U.S.)
| Milestone | IGlar/IDeg |
|---|---|
| Started | 143 |
| Exposed | 142 |
| Full analysis set | 129 |
| Completed | 122 |
| Not completed | 21 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Withdrawal criteria | 10 |
| Withdrew: Unclassified | 7 |
HbA1C at week 4 and 16
| percentage of glycosylated haemoglobin | IGlar/IDeg |
|---|---|
| Week 4 (N=128) (IGlar) | 7.4 ± 1.0 |
| Week 16 (N=122)(IDeg) | 7.2 ± 1.1 |
FPG at week 4 and 16
| mmol/L | IGlar/IDeg |
|---|---|
| Week 4 (N=128) (IGlar) | 7.0 ± 2.3 |
| Week 16 (N=122) (IDeg) | 6.3 ± 2.2 |
Change from baseline in body weight after week 4 and after week 16
| kg | IGlar/IDeg |
|---|---|
| Week 4(N= 142) (IGlar) | 0.1 ± 0.4 |
| Week 16 (N=129) (IDeg) | 0.6 ± 2.2 |
Corresponds to rate of AEs per 100 patient years of exposure. Mild AEs: no or transient symptoms, no interference with subject's daily activities. Moderate AEs: marked symptoms, moderate interference with subject's daily activities. Severe AEs: considerable interference with subject's daily activities, unacceptable. Serious adverse event (SAE): AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect
| events per 100 patient years | IGlar/IDeg |
|---|---|
| Adverse events (N=142)(week 4)(IGlar) | 370 |
| Serious AEs (N=142 ) (week 4)(IGlar) | 9 |
| Severe AEs (N=142)(week 4) (IGlar) | 19 |
| Moderate AEs (N=142) (week 4)(IGlar) | 102 |
| Mild AEs (N=142)(week 4) (IGlar) | 250 |
| Fatal AEs (N=142) (week 4) (IGlar) | 0 |
| Adverse events (N=129) (week 16) (IDeg) | 424 |
| Serious AEs (n=129) (week 16) (IDeg) | 7 |
| Severe AEs (N=129) (week 16) (IDeg) | 10 |
| Moderate AEs (N=129) (week 16) (IDeg) | 132 |
| Mild AEs (N=129) (week 16) (IDeg) | 280 |
| Fatal AEs (N=129) (week 16) (IDeg) | 0 |
| Adverse Events (N=142) (Total) | 409 |
| Serious AEs (N=142) (Total) | 8 |
| Severe AEs (N=142) (Total) | 13 |
| Moderate AEs (N=142) (Total) | 124 |
| Mild AEs (N=142) (Total) | 273 |
| Fatal AEs (N=142)(Total) | 0 |
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.
| episodes per 100 patient years | IGlar/IDeg |
|---|---|
| IGlar (N=142) (week 4) | 453 |
| IDeg (N=129) (week 16) | 424 |
Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occuring between 00:01 and 05:59 a.m.
| episodes per 100 patient years | IGlar/IDeg |
|---|---|
| IGlar (week 4) (N=142) | 111 |
| IDeg (week 16) (N=129) | 83 |
Collected over The adverse events were collected in a time frame of 0-4 weeks (IGlar) and 4-16 weeks (IDeg 3TW). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGlar/IDeg | — | 3/142 (2.1%) | 0/142 (0%) |
| Event | IGlar/IDeg |
|---|---|
| Cholelithiaisis (IDeg)Hepatobiliary disorders | 1/129 |
| Carotid artery occlusion (IDeg)Nervous system disorders | 1/129 |
| Cholelithiasis (Total)Hepatobiliary disorders | 1/142 |
| Lumbar spinal stenosis (IGlar)Musculoskeletal and connective tissue disorders | 1/142 |
| Lumbar spinal stenosis (Total)Musculoskeletal and connective tissue disorders | 1/142 |
| Carotid artery occlusion (Total)Nervous system disorders | 1/142 |
| Cholelithiasis (IGlar)Hepatobiliary disorders | 0/142 |
| Lumbar spinal stenosis (IDeg)Musculoskeletal and connective tissue disorders | 0/129 |
| Carotid artery occlusion (IGlar)Nervous system disorders | 0/142 |
Full Analysis set (FAS)-Includes 129 subjects only as 13 subjects did not receive IDeg.
| Age, Continuous(years) | IGlar/IDeg |
|---|---|
| Mean | 58.7 ± 10.2 |
| Sex: Female, Male(Participants) | IGlar/IDeg |
|---|---|
| Female | 43 |
| Male | 86 |
| HbA1c (glycosylated haemoglobin) at baseline(percentage of glycosylated haemoglobin) | IGlar/IDeg |
|---|---|
| Mean | 7.5 ± 1.1 |
| Fasting plasma glucose (FPG) at baseline(mmol/L) | IGlar/IDeg |
|---|---|
| Mean | 7.0 ± 2.2 |
| Body weight at baseline(kg) | IGlar/IDeg |
|---|---|
| Mean | 99.3 ± 20.4 |
The record gives a start of Jun 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 5 years 2 months after primary completion. A results delay was requested in Feb 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Glargine